Skip Nav Destination
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity
Issue Archive
May 17 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Review Article
Clinical Trials and Observations
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Clinical Trials & Observations
John P. Leonard,Ann S. LaCasce,Mitchell R. Smith,Ariela Noy,Lucian R. Chirieac,Scott J. Rodig,Jian Q. Yu,Shankar Vallabhajosula,Heiko Schoder,Patricia English,Donna S. Neuberg,Peter Martin,Michael M. Millenson,Scott A. Ely,Rachel Courtney,Naveed Shaik,Keith D. Wilner,Sophia Randolph,Annick D. Van den Abbeele,Selina Y. Chen-Kiang,Jeffrey T. Yap,Geoffrey I. Shapiro
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Clinical Trials & Observations
Suzanne Lentzsch,Amy O'Sullivan,Ryan C. Kennedy,Mohammad Abbas,Lijun Dai,Silvana Lalo Pregja,Steve Burt,Michael Boyiadzis,G. David Roodman,Markus Y. Mapara,Mounzer Agha,John Waas,Yongli Shuai,Daniel Normolle,Jeffrey A. Zonder
Hematopoiesis and Stem Cells
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
Christian Pecquet,Carmen C. Diaconu,Judith Staerk,Michael Girardot,Caroline Marty,Yohan Royer,Jean-Philippe Defour,Alexandra Dusa,Rodolphe Besancenot,Stephane Giraudier,Jean-Luc Villeval,Laurent Knoops,Pierre J. Courtoy,William Vainchenker,Stefan N. Constantinescu
Immunobiology
Comprehensive analysis of unique cases with extraordinary control over HIV replication
Daniel Mendoza,Sarah A. Johnson,Bennett A. Peterson,Ven Natarajan,Maria Salgado,Robin L. Dewar,Peter D. Burbelo,Nicole A. Doria-Rose,Erin H. Graf,Jamieson H. Greenwald,Jessica N. Hodge,William L. Thompson,Nancy A. Cogliano,Cheryl L. Chairez,Catherine A. Rehm,Sara Jones,Claire W. Hallahan,Joseph A. Kovacs,Irini Sereti,Omar Sued,Sheila A. Peel,Robert J. O'Connell,Una O'Doherty,Tae-Wook Chun,Mark Connors,Stephen A. Migueles
KAP1 regulates gene networks controlling mouse B-lymphoid cell differentiation and function
Francesca R. Santoni de Sio,Joanna Massacand,Isabelle Barde,Sandra Offner,Andrea Corsinotti,Adamandia Kapopoulou,Karolina Bojkowska,Antonis Dagklis,Marylise Fernandez,Paolo Ghia,James H. Thomas,Daniel Pinschewer,Nicola Harris,Didier Trono
Lymphoid Neoplasia
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
Clinical Trials & Observations
Wendy Cuccuini,Josette Briere,Nicolas Mounier,Hans-Ullrich Voelker,Andreas Rosenwald,Christer Sundstrom,Sergio Cogliatti,Edouard Hirchaud,Loic Ysebaert,Dominique Bron,Jean Soulier,Philippe Gaulard,Remi Houlgatte,Christian Gisselbrecht,Catherine Thieblemont
Myeloid Neoplasia
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Clinical Trials & Observations
Alireza Eghtedar,Srdan Verstovsek,Zeev Estrov,Jan Burger,Jorge Cortes,Carol Bivins,Stefan Faderl,Alessandra Ferrajoli,Gautam Borthakur,Solly George,Peggy A. Scherle,Robert C. Newton,Hagop M. Kantarjian,Farhad Ravandi
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity
Brief Report
Ulrike Bacher,Susanne Schnittger,Katja Macijewski,Vera Grossmann,Alexander Kohlmann,Tamara Alpermann,Andreas Kowarsch,Niroshan Nadarajah,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach
Phagocytes, Granulocytes, and Myelopoiesis
Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis
Sarah M. Lo,Murim Choi,Jun Liu,Dhanpat Jain,Rolf G. Boot,Wouter W. Kallemeijn,Johannes M. F. G. Aerts,Farzana Pashankar,Gary M. Kupfer,Shrikant Mane,Richard P. Lifton,Pramod K. Mistry
Platelets and Thrombopoiesis
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis
Sergei Zaitsev,M. Anna Kowalska,Michael Neyman,Ronald Carnemolla,Samira Tliba,Bi-Sen Ding,Aaron Stonestrom,Dirk Spitzer,John P. Atkinson,Mortimer Poncz,Douglas B. Cines,Charles T. Esmon,Vladimir R. Muzykantov
Transplantation
Regulation of acute graft-versus-host disease by microRNA-155
Parvathi Ranganathan,Catherine E. A. Heaphy,Stefan Costinean,Nicole Stauffer,Caroline Na,Mehdi Hamadani,Ramasamy Santhanam,Charlene Mao,Patricia A. Taylor,Sukhinder Sandhu,Gang He,Arwa Shana'ah,Gerard J. Nuovo,Alessandro Lagana,Luciano Cascione,Susanna Obad,Oliver Broom,Sakari Kauppinen,John C. Byrd,Michael Caligiuri,Danilo Perrotti,Gregg A. Hadley,Guido Marcucci,Steven M. Devine,Bruce R. Blazar,Carlo M. Croce,Ramiro Garzon
Vascular Biology
Correspondence
Response: Breslow thickness and excision interval affect the activation state of Langerhans cells in melanoma sentinel lymph nodes
Mari F. C. M. van den Hout,Bas D. Koster,Berbel J. R. Sluijter,Paul A. M. van Leeuwen,Sybren Meijer,Monique Petrousjka van den Tol,Alfons J. M. van den Eertwegh,Rik J. Scheper,Rieneke van de Ven,Tanja D. de Gruijl
Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT
Cristina Toffalori,Irene Cavattoni,Sara Deola,Sara Mastaglio,Fabio Giglio,Benedetta Mazzi,Andrea Assanelli,Jacopo Peccatori,Claudio Bordignon,Chiara Bonini,Sergio Cortelazzo,Fabio Ciceri,Katharina Fleischhauer,Luca Vago
-
Cover Image
Cover Image
![issue cover]()
Treatment of primary mouse astrocytes (GFAP immunostaining; white) with t-PA and plasminogen induces marked morphologic changes (top panel) which are blocked by treatment with the Rho kinase inhibitor HA1077 (bottom panel). Nuclei are highlighted in red. See the article by Niego et al on page 4752.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
